The DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
New drugs for asthma
Open accessAbstract
Current therapy for asthma with inhaled corticosteroids and long-acting inhaled β(2)-agonists is highly effective, safe, and relatively inexpensive, but many patients remain poorly controlled. Most advances have been through improving these drug classes and a major developmental hurdle is to improve existing drug classes. Major unmet needs include better treatment of severe asthma (which has some similarity to chronic obstructive pulmonary disease), as well as curative therapies for mild to moderate asthma that do not result in the return of symptoms when the treatment is stopped. Several new treatments are in development, but many are specific, targeting a single mediator or receptor, and are unlikely to have a major clinical impact, although they may be effective in specific asthma phenotypes (endotypes). Drugs with more widespread effects, such as kinase inhibitors, may be more effective but have a greater risk of side effects so inhaled delivery may be needed. Several new treatments target the underlying allergic/immune process and would treat concomitant allergic diseases. Improved immunotherapy approaches have the potential for disease modification, although prospects for a cure are currently remote.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Adcock, I. M., Nasuhara, Y., Stevens, D. A., & Barnes, P. J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702613 · Cited by 140
Self-citationRetractedInterleukin-13: Central Mediator of Allergic Asthma
Wills-Karp, M., Luyimbazi, J., Xu, X., Schofield, B., Neben, T. Y., Karp, C. L., & Donaldson, D. D. (1998) · Science · doi:10.1126/science.282.5397.2258 · Cited by 2,617
The Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Self-citationJonat, C., Rahmsdorf, H. J., Park, K.-K., Cato, A. C. B., Gebel, S., Ponta, H., & Herrlich, P. (1990) · Cell · doi:10.1016/0092-8674(90)90395-u · Cited by 1,566
Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor
Schüle, R., Rangarajan, P., Kliewer, S., Ransone, L. J., Bolado, J., Yang, N., Verma, I. M., & Evans, R. M. (1990) · Cell · doi:10.1016/0092-8674(90)90397-w · Cited by 1,221
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197
Hirai, H., Tanaka, K., Yoshie, O., Ogawa, K., Kenmotsu, K., Takamori, Y., Ichimasa, M., Sugamura, K., Nakamura, M., Takano, S., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.255 · Cited by 1,099
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Regular inhaled beta-agonist treatment in bronchial asthma
Sears, M. R., Taylor, D. R., Print, C. G., Lake, D. C., Li, Q., Flannery, E. M., Yates, D. M., Lucas, M. K., & Herbison, G. P. (1990) · The Lancet · doi:10.1016/0140-6736(90)93098-a · Cited by 1,065
Cited by
After asthma: redefining airways diseases
Pavord, I. D., Beasley, R., Agusti, A., Anderson, G. P., Bel, E., Brusselle, G., Cullinan, P., Custovic, A., Ducharme, F. M., Fahy, J. V., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)30879-6 · Cited by 1,073
Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation
Talbot, S., Abdulnour, R.-E. E., Burkett, P. R., Lee, S., Cronin, S. J. F., Pascal, M. A., Laedermann, C., Foster, S. L., Tran, J. V., Lai, N., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.007 · Cited by 452
Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances: Miniperspective
Reis, J., Gaspar, A., Milhazes, N., & Borges, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01720 · Cited by 414
Update on glucocorticoid action and resistance
Ito, K., Chung, K. F., & Adcock, I. M. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.032 · Cited by 397
Phosphodiesterases in the CNS: targets for drug development
Menniti, F. S., Faraci, W. S., & Schmidt, C. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2058 · Cited by 391
Third International Pediatric Consensus statement on the management of childhood asthma
Warner, J. O., Naspitz, C. K., & Cropp, G. J. A. (1998) · Pediatric Pulmonology · doi:10.1002/(sici)1099-0496(199801)25:1<1::aid-ppul1>3.0.co;2-s · Cited by 389
Pathophysiology of allergic inflammation
Barnes, P. J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01020.x · Cited by 361
Self-citationCorticosteroids: The drugs to beat
Barnes, P. J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.052 · Cited by 301
Self-citationIdzko, M., Hammad, H., Nimwegen, M. V., Kool, M., Müller, T., Soullié, T., Willart, M. A. M., Hijdra, D., Hoogsteden, H. C., & Lambrecht, B. N. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28295 · Cited by 258
Asthma: pathogenesis and novel drugs for treatment
Olin, J. T., & Wechsler, M. E. (2014) · BMJ · doi:10.1136/bmj.g5517 · Cited by 256
Erin, E. M., Zacharasiewicz, A. S., Nicholson, G. C., Tan, A. J., Higgins, L. A., Williams, T. J., Murdoch, R. D., Durham, S. R., Barnes, P. J., & Hansel, T. T. (2005) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2005.02381.x · Cited by 76
Self-citation
Metadata
- Authors
- Barnes, P. J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-10
- Volume
- 3
- Issue
- 10
- Pages
- 831-844
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W283814565
- Cited by
- 280
- References
- 167
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.